Oct. 25 at 2:46 PM
$PHAT just released
Phathom Pharmaceuticals announced positive results related to its medication, VOQUEZNA (vonoprazan), for treating nighttime gastroesophageal reflux disease (GERD) symptoms, as reported in the American Journal of Gastroenterology. In the Phase 3 pHalcon-NERD-301 trial, VOQUEZNA provided rapid and sustained relief from nighttime GERD symptoms, with significant improvements in heartburn-free nights observed after the first dose and maintained over 24 weeks. The trial findings revealed that VOQUEZNA led to clinically meaningful reductions in nocturnal symptom severity and enhanced sleep quality for patients with Non-Erosive Reflux Disease (NERD). The drug was well tolerated with manageable side effects, adding to the evidence of its effectiveness in a patient population that often struggles with existing therapies. The publication aims to highlight VOQUEZNA's potential role in addressing an underrecognized aspect of GERD and improving patient quality of life.
